Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
VanEck Rare Earth/Strategic MetalsTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.07B), while VanEck Rare Earth/Strategic Metals trades at $77.3. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.

ACADREMX
Market Cap
$5.07B
Sector
HealthSector/Thematic
52-Week High
$29.41$109.53
52-Week Low
$20.06$56.60
Enterprise Value
$4.19B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.

VanEck Rare Earth/Strategic Metals

REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.24, down 1.54% with a bullish technical signal supported by moving averages. The ETF provides exposure to 38 global rare earth companies amid growing U.S. efforts to secure critical mineral supply chains. Recent news highlights Energy Fuels' Utah plant expansion and ongoing geopolitical focus on reducing China's rare earth dominance.

Outlook remains tied to U.S. industrial policy and rare earth demand, though high volatility (~50% annualized) and China concentration pose risks. Investor sentiment is mixed, balancing strategic importance against execution challenges in building domestic supply chains.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About VanEck Rare Earth/Strategic Metals

REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.

Read more on REMX